Therapeutics Initiative |

15 Feb Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study

Posted at 10:00h in PharmacoEpidemiology 0 Comments

Anat Fisher, Jason D. Kim, Colin R. Dormuth CMAJ Open February 15, 2022 10 (1) E109-E118; DOI: 10.9778/cmajo.20200319 Abstract Background: In 2019, British Columbia’s public drug plan, PharmaCare, was the first in Canada to implement a nonmedical switching...

27 Jan Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept—a cohort study in British Columbia

Posted at 15:56h in PharmacoEpidemiology 0 Comments

Fisher, A., Kim, J.D., Carney, G. et al. Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept—a cohort study in British Columbia. BMC Rheumatol 6, 5 (2022)...

psoriatic arthritis Tag

15 Feb Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study

27 Jan Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept—a cohort study in British Columbia

Contact

Subscribe for Updates